Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Autolus Therapeutics and Precision BioSciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
| Precision BioSciences | 1 | 0 | 4 | 0 | 2.60 |
Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 549.35%. Precision BioSciences has a consensus target price of $32.25, indicating a potential upside of 385.69%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Autolus Therapeutics is more favorable than Precision BioSciences.
Volatility and Risk
Autolus Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Valuation and Earnings
This table compares Autolus Therapeutics and Precision BioSciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autolus Therapeutics | $117.39 million | 3.49 | -$287.53 million | ($1.06) | -1.45 |
| Precision BioSciences | $34.26 million | 5.35 | -$45.72 million | ($2.80) | -2.37 |
Precision BioSciences has lower revenue, but higher earnings than Autolus Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Autolus Therapeutics and Precision BioSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| Precision BioSciences | -96.73% | -72.52% | -32.25% |
Summary
Autolus Therapeutics beats Precision BioSciences on 9 of the 15 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Precision BioSciences
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
